Oligometastatic prostate cancer is a subtype of metastatic disease that generally is defined by the presence of 5 or fewer metastatic lesions. Metastatic prostate cancer currently is treated with androgen deprivation therapy and additional systemic therapy, such as novel antiandrogen medications or chemotherapy.
Several studies evaluated prostate cancer (PCa) outcomes in Black men on active surveillance (AS); most studies contained few Black men and results were conflicting. We performed a systematic review and meta-analyze of race and outcomes on AS.
The standard method of evaluating the lubricity of intermittent urinary catheters with coefficient of friction (CoF) testing is not physiologically relevant, while there is also a dearth of published research on catheter-associated urethral micro-trauma.
(UroToday.com) In this presentation during the thematic session at the 2021 European Association of Urology (EAU) annual meeting, focusing on immunotherapy in urothelial cancer, Dr. Thomas Powles reviews predictive markers for response in urothelial cancer.
(UroToday.com) Dr. Johann De Bono provides us with an overview of prostate cancer molecular testing, along with guidance on which patients and when we should be obtaining them.
(UroToday.com) In this first talk of the thematic session focusing on treatment sequencing in metastatic prostate cancer, Dr. Ploussard provided a summary of key concepts in the monitoring of prostate cancer and when to change management.
(UroToday.com) Dr. Karim Fizazi finished off the thematic session of Treatment Sequencing in Metastatic Prostate Cancer with a presentation on the role of PSMA in diagnostics and treatment of metastatic prostate cancer. PSMA is a transmembrane protein that is often highly expressed by prostate cancer cells and not express by most normal tissues (exception = salivary glands). Expression […]
(UroToday.com) Dr. Gero Kramer reviews the systemic treatment options for metastatic castration-resistant prostate cancer (mCRPC) and highlights some recent developments.
(UroToday.com) In this abstract, Ms. Spieler looks at the timing of adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible patients with pT3-4 or N+M0 urothelial carcinoma following radical cystectomy.
(UroToday.com) In this abstract, Dr. Gschwend reports the impact of nivolumab vs. placebo on health-related quality of life (HRQoL) outcomes in the CheckMate-274 trial.1 In the phase 3, randomized, double-blind, multicenter CheckMate 274 trial (NCT02632409), patients with high-risk muscle-invasive urothelial carcinoma (MIUC) who had undergone radical resection were randomized 1:1 to adjuvant nivolumab (NIVO) 240 mg Q2W […]
